Early detection of prostate cancer: Is serum PSA testing alone sufficient?;Früherkennung von Prostatakarzinomen: Ist die Untersuchung des Serum-PSA alleine ausreichend?

Urologe - Ausgabe A

Volumn 49, Issue 11, 2010, Pages 1351-1355

  Borgermann C ^a,b   Vom Dorp, F ^a   Breuer, G ^b   Kliner, S ^a,b   Rubben H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Krankenhaus Duren gem GmbH   (Germany)

Author keywords

Prostate cancer; Prostate cancer antigen 3, human; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER SCREENING; HUMAN; PROSTATE CANCER; REVIEW;

HUMANS; MALE; NEOPLASM PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 78650184186     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-010-2394-5     Document Type: Review

References (32)

1. Catalona WJ, Richie J P, Ahmann FR et al (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6, 630 men. J Urol 151(5):1283-1290
2. Luboldt HJ, Altwein JE, Bichler KH et al (1999) Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle. Urologe A 38(2):114-123
3. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320-1328
4. Andriole GL, Crawford ED, Grubb RL et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-1319
5. Harris R, Lohr KN, Beck R et al (2002) Screening for prostate cancer. Agency for Healthcare Research and Quality, Rockville, Md
6. Mistry K, Cable G (2003) Meta-analysis of prostatespecific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 16(2):95-101
7. Auvinen A, Maattanen L, Finne P et al (2004) Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. Int J Cancer 111(6):940-943
8. Candas B, Cusan L, Gomez JL et al (2000) Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 45(1):19-35
9. Maattanen L, Hakama M, Tammela TL et al (2007) Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer 96(1):56-60
10. McLernon DJ, Donnan PT, Gray M et al (2006) Receiver operating characteristics of the prostate specific antigen test in an unselected population. J Med Screen 13(2):102-107
11. Greene KL, Albertsen PC, Babaian RJ et al (2009) Prostate specific antigen best practice statement: 2009 update. J Urol 182(5):2232-2241
12. Carter HB, Pearson JD, Metter EJ et al (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267(16):2215-2220
13. Berger A P, Deibl M, Strasak A et al (2007) Largescale study of clinical impact of PSA velocity: longterm PSA kinetics as method of differentiating men with from those without prostate cancer. Urology 69(1):134-138
14. Raaijmakers R, Wildhagen M F, Ito K et al (2004) Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 63(2):316-320
15. Loeb S, Roehl KA, Catalona WJ, Nadler RB (2007) Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 177(3):899-902 (Pubitemid 46223578)
16. Soletormos G, Semjonow A, Sibley PE et al (2005) Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 51(8):1342-1351
17. Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level
18. Catalona WJ, Partin AW, Slawin KM et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279(19):1542-1547
19. Partin AW, Catalona WJ, Southwick PC et al (1996) Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48 (6 A Suppl): 55-61
20. Borgermann C, Swoboda A, Luboldt HJ et al (2009) The f/t-PSA ratio in diagnosis of in-patients and out-patients: a unitary cutoff value is not useful! World J Urol 27(5):581-585
21. Stephan C, Lein M, Jung K et al (1997) The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 79(1):104-109
22. Stimac G, Reljic A, Spajic B et al (2009) Aggressiveness of inflammation in histological prostatitis - correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy. Scott Med J 54(3):8-12
23. Semjonow A, Hamm M, Rathert P (1993) The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer. Urologe A 32(3):250-253
24. Wolff JM, Boeckmann W, Effert PJ et al (1995) Evaluation of patients with diseases of the prostate using prostate-specific antigen density. Br J Urol 76(1):41-46
25. Seaman E, Whang M, Olsson CA et al (1993) PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 20(4):653-663
26. Brawer MK, Aramburu EA, Chen GL et al (1993) The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 150 (2 Pt 1):369-373
27. Thon W F, Gadban F, Truss MC et al (1996) Prostate-specific antigen density-a reliable parameter for the detection of prostate cancer? World J Urol 14(1):53-58
28. Semjonow A, Hamm M, Rathert P, Hertle L (1994) Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer. Br J Urol 73(5):538-543
29. Gils MP van, Hessels D, Hooij O van et al (2007) The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13(3):939-943
30. Hessels D, Klein Gunnewiek JM, O I van et al (2003) DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44(1):8-15
31. Tosoian JJ, Loeb S, Kettermann A et al (2010) Accuracy of PCA3 measurement in predicting shortterm biopsy progression in an active surveillance program. J Urol 183(2):534-538
32. Sardana G, Dowell B, Diamandis EP (2008) Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 54(12):1951-1960